亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002370 亚太药业

交易中 07-24 14:16:39

{"stockData":{"symbol":"002370","market":"SZ","secType":"STK","nameCN":"亚太药业","latestPrice":2.26,"timestamp":1721801799000,"preClose":2.32,"halted":0,"volume":6838300,"delay":0,"floatShares":609000000,"shares":609000000,"eps":-0.0202,"marketStatus":"交易中","marketStatusCode":2,"change":-0.06,"latestTime":"07-24 14:16:39","open":2.32,"high":2.35,"low":2.25,"amount":15597000,"amplitude":0.0431,"askPrice":2.27,"askSize":471,"bidPrice":2.26,"bidSize":15,"shortable":0,"etf":0,"ttmEps":-0.0202,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721804400000},"adr":0,"adjPreClose":2.32,"symbolType":"stock","openAndCloseTimeList":[[1721784600000,1721791800000],[1721797200000,1721804400000]],"highLimit":2.55,"lowLimit":2.09,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":609180082,"pbRate":3.22,"roa":"--","roe":"--","epsLYR":-0.02,"committee":-0.123149,"marketValue":1377000000,"floatMarketCap":1377000000,"peRate":-111.881192,"changeRate":-0.0259,"turnoverRate":0.0112,"status":1},"requestUrl":"/m/hq/s/002370","defaultTab":"news","newsList":[{"id":"2452217086","title":"亚太药业：股东人数公司将按照相关规定在定期报告中披露相应时点的股东信息，敬请关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2452217086","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452217086?lang=zh_cn&edition=full","pubTime":"2024-07-18 17:02","pubTimestamp":1721293376,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业07月18日在投资者关系平台上答复投资者关心的问题。股东人数公司将按照相关规定在定期报告中披露相应时点的股东信息，敬请关注，谢谢！投资者：董秘你好，我是贵公司股东，公司半年报营收还没有超过3000万，根据退市新规年营收低于3亿，将被强制退市，公司对目前经营状态，是否有相应的措施，给予支持亚太药业的投资者以信心亚太药业董秘：您好！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800036415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2450560336","title":"亚太药业：公司对外投资者电话为：0575-84810101","url":"https://stock-news.laohu8.com/highlight/detail?id=2450560336","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450560336?lang=zh_cn&edition=full","pubTime":"2024-07-11 17:03","pubTimestamp":1720688623,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业07月11日在投资者关系平台上答复投资者关心的问题。公司对外投资者电话为：0575-84810101，谢谢！公司控股股东、实际控制人、董事、监事、高级管理人员不存在融资融券买卖本公司股票以及转融通出借公司股票的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100033521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2450281588","title":"亚太药业：预计2024年1-6月归属净利润盈利450万元至650万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450281588","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450281588?lang=zh_cn&edition=full","pubTime":"2024-07-10 22:01","pubTimestamp":1720620074,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业发布业绩预告，预计2024年1-6月归属净利润盈利450万元至650万元。亚太药业2024年一季报显示，公司主营收入1.13亿元，同比下降8.8%；归母净利润-299.84万元，同比下降14.49%；扣非净利润-221.13万元，同比上升62.17%；负债率57.59%，财务费用520.36万元，毛利率32.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000047128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2450813079","title":"亚太药业最新公告：预计上半年净利同比下降67%-77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450813079","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450813079?lang=zh_cn&edition=full","pubTime":"2024-07-10 22:00","pubTimestamp":1720620004,"startTime":"0","endTime":"0","summary":"亚太药业公告，预计上半年净利450万元–650万元，同比下降67.12%-77.23%。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000047064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2450603897","title":"亚太药业(002370.SZ)发预减，预计半年度净利润450万元-650万元，同比下降67.12%-77.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450603897","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450603897?lang=zh_cn&edition=full","pubTime":"2024-07-10 21:07","pubTimestamp":1720616851,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业 发布公告，公司预计2024年半年度归属于上市公司股东的净利润450万元-650万元，同比下降67.12%-77.23%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002370"],"gpt_icon":0},{"id":"2450188613","title":"亚太药业（002370）7月9日主力资金净买入31.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450188613","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450188613?lang=zh_cn&edition=full","pubTime":"2024-07-10 09:20","pubTimestamp":1720574453,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月9日收盘，亚太药业报收于2.41元，下跌1.63%，换手率1.18%，成交量7.2万手，成交额1727.8万元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入34.78万元，融资偿还50.14万元，融资净偿还15.36万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000015437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2449402601","title":"亚太药业（002370）7月4日主力资金净卖出152.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449402601","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449402601?lang=zh_cn&edition=full","pubTime":"2024-07-05 09:21","pubTimestamp":1720142516,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月4日收盘，亚太药业报收于2.46元，下跌5.02%，换手率1.13%，成交量6.88万手，成交额1721.0万元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入43.07万元，融资偿还26.75万元，融资净买入16.32万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500012797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2448918230","title":"亚太药业最新公告：子公司上海新生源被法院宣告破产","url":"https://stock-news.laohu8.com/highlight/detail?id=2448918230","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448918230?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:19","pubTimestamp":1719908344,"startTime":"0","endTime":"0","summary":"亚太药业公告，子公司上海新高峰生物医药有限公司之全资子公司上海新生源医药集团有限公司于2024年7月1日收到上海市浦东新区人民法院送达的（2023）沪0115破58号之四《民事裁定书》，法院宣告上海新生源破产，终结上海新生源破产清算程序。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200023716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2437402677","title":"亚太药业（002370）5月23日主力资金净卖出704.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437402677","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437402677?lang=zh_cn&edition=full","pubTime":"2024-05-24 09:22","pubTimestamp":1716513736,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月23日收盘，亚太药业报收于3.11元，下跌4.31%，换手率1.79%，成交量10.88万手，成交额3429.1万元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入83.3万元，融资偿还50.87万元，融资净买入32.43万元，连续3日净买入累计56.48万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052400015523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2437492499","title":"亚太药业：如涉及下修转股价，公司将按相关规定履行信息披露义务，敬请关注公司公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2437492499","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437492499?lang=zh_cn&edition=full","pubTime":"2024-05-21 17:05","pubTimestamp":1716282315,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业05月21日在投资者关系平台上答复投资者关心的问题。如涉及下修转股价，公司将按相关规定履行信息披露义务，敬请关注公司公告，谢谢。在可转债存续期间，将合理安排和使用资金，并做好相应风险防范，谢谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052100028720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2433316475","title":"亚太药业(002370.SZ)控股股东累计增持2.01%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2433316475","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433316475?lang=zh_cn&edition=full","pubTime":"2024-05-06 21:08","pubTimestamp":1715000929,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)发布公告，公司于2024年5月6日收到公司控股股东宁波富邦控股集团有限公司(简称“富邦集团”)的《关于增持亚太药业股份计划实施进展情况的告知函》，截至本公告披露日，本次增持计划时间已过半，公司控股股东富邦集团通过深圳证券交易所系统以集中竞价交易方式累计增持公司股份12,270,000股，占公司总股本的2.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2433847376","title":"5月6日亚太药业发布公告，其股东增持210万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433847376","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433847376?lang=zh_cn&edition=full","pubTime":"2024-05-06 21:00","pubTimestamp":1715000454,"startTime":"0","endTime":"0","summary":"证券之星消息，5月6日亚太药业发布公告《亚太药业:关于控股股东增持计划进展的公告》，其股东宁波富邦控股集团有限公司于2024年2月8日至2024年5月6日间合计增持210.0万股，占公司目前总股本的0.3447%，变动期间该股股价上涨15.02%，截止5月6日收盘报3.37元。股东增减持详情见下表：根据亚太药业2024年一季报公布的十大股东详情如下：以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600026376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2430784707","title":"图解亚太药业一季报：第一季度单季净利润同比减14.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430784707","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430784707?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:21","pubTimestamp":1714155685,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业2024年一季报显示，公司主营收入1.13亿元，同比下降8.8%；归母净利润-299.84万元，同比下降14.49%；扣非净利润-221.13万元，同比上升62.17%；负债率57.59%，财务费用520.36万元，毛利率32.68%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700004083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2430026270","title":"亚太药业(002370.SZ)发布一季度业绩，净亏损299.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430026270","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430026270?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:53","pubTimestamp":1714139586,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)发布2024年一季度报告，报告期内实现营业收入1.13亿元，同比下降8.80%。归属于上市公司股东净亏损299.84万元。归属于上市公司股东的扣除非经常性损益净亏损221.13万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2423498832","title":"亚太药业(002370.SZ)发2023年度业绩，净亏损1187.70万元，同比亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2423498832","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2423498832?lang=zh_cn&edition=full","pubTime":"2024-03-29 22:08","pubTimestamp":1711721280,"startTime":"0","endTime":"0","summary":"亚太药业发布2023年年度报告，报告期内公司实现营业收入4.21亿元，同比增长12.64%;归属于上市公司股东的净亏损1187.70万元，同比亏损收窄;归属于上市公司股东的扣除非经常性损益的净亏损6894.45万元;基本每股亏损0.02元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-29/doc-inapzekn1058041.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-29/doc-inapzekn1058041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2407383664","title":"亚太药业(002370.SZ)收到注射用阿昔洛韦一致性评价受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2407383664","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2407383664?lang=zh_cn&edition=full","pubTime":"2024-01-29 16:01","pubTimestamp":1706515260,"startTime":"0","endTime":"0","summary":"亚太药业发布公告，公司于近日收到国家药品监督管理局下发的关于注射用阿昔洛韦一致性评价的受理通知书。公告称，注射用阿昔洛韦被国家药品监督管理局受理，标志着该品种一致性评价工作进入了审评阶段，公司将积极推进后续相关工作，如顺利通过一致性评价将增加其市场竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-29/doc-inafeqqe3760682.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-29/doc-inafeqqe3760682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002370","BK0132","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-03-16","address":"浙江省绍兴市柯桥区群贤路2003号1501室","stockEarnings":[{"period":"1week","weight":-0.0333},{"period":"1month","weight":-0.0937},{"period":"3month","weight":-0.2611},{"period":"6month","weight":-0.399},{"period":"1year","weight":-0.4642},{"period":"ytd","weight":-0.4592}],"companyName":"浙江亚太药业股份有限公司","boardCode":"AI0027","perCapita":"9431股","boardName":"医药制造业","registeredCapital":"60918万元","compareEarnings":[{"period":"1week","weight":-0.0205},{"period":"1month","weight":-0.0276},{"period":"3month","weight":-0.0425},{"period":"6month","weight":0.0032},{"period":"1year","weight":-0.0786},{"period":"ytd","weight":-0.02}],"survey":"　　浙江亚太药业股份有限公司主要从事医药制造业务，包括化学制剂、化学原料药的研发、生产和销售。公司主要产品包括抗阿莫西林克拉维酸钾分散片、阿奇霉素分散片、注射用阿奇霉素、罗红霉素胶囊、注射用头孢唑肟钠等。罗红霉素胶囊、头孢氨苄胶囊、阿奇霉素分散片及注射用阿奇霉素为本公司的主导产品。","serverTime":1721801802784,"listedPrice":16,"stockholders":"64587人(较上一季度增加0.73%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚太药业,002370,亚太药业股票,亚太药业股票老虎,亚太药业股票老虎国际,亚太药业行情,亚太药业股票行情,亚太药业股价,亚太药业股市,亚太药业股票价格,亚太药业股票交易,亚太药业股票购买,亚太药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}